Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
Frequently asked questions
What sector does Novacyt (ALNOV) operate in?
Novacyt belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Novacyt (ALNOV) current stock price?
As of the latest data, Novacyt stock price is €0.51, with a previous close of €0.51. Novacyt gained €0.00 in the last trading session, representing a 0.19% increase.
What is Novacyt (ALNOV) current market capitalization?
Novacyt market cap is approximately 37.27 million.
What is Novacyt (ALNOV) Earnings Per Share (EPS)?
The trailing EPS is -€0.39.
Does Novacyt (ALNOV) pay dividends?
No. Novacyt does not pay a dividend.
What is Novacyt (ALNOV) beta (volatility) score?
Novacyt has a beta of 1.106, meaning its volatility is roughly in line with the market.
